TY - JOUR T1 - Advances in treatment of chronic hepatitis C: ‘Pegylated’ interferons JF - Cleveland Clinic Journal of Medicine JO - Cleve Clin J Med SP - 155 LP - 159 VL - 69 IS - 2 AU - Khavir A. Sharieff AU - David Duncan AU - Zobair Younossi Y1 - 2002/02/01 UR - http://www.ccjm.org/content/69/2/155.abstract N2 - New regimens consisting of pegylated interferons plus ribavirin may produce a sustained virologic response in more than 50% of cases of chronic hepatitis C. In contrast, the combination of standard interferon alfa and ribavirin, which was the standard of care until recently, produced a sustained virologic response in 35% to 40% of cases. As the efficacy of newer regimens improves, additional steps to adequately manage their side effects and maximize adherence may become crucial. ER -